Phase 2 Crohn's Disease and Colitis Trial, Recruiting NCT07483073 Sponsor: Eli Lilly and Company Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 2 Crohn's Disease and Colitis Trial, Recruiting

NCT07483073
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Ulcerative Colitis (UC) or Crohn's Disease (CD) for at least 3 months, confirmed by a camera examination of your gut and a tissue sample test.
  • If you have UC: your disease is moderately to severely active, based on specific scoring measurements taken during a gut camera examination done within the last 21 days.
  • If you have CD: your disease is moderately to severely active, based on specific activity scores and a gut camera examination done within the last 21 days.
  • Previous treatments for your condition (such as steroids, immune-suppressing medicines, or other advanced therapies) have not worked well enough, stopped working, or caused you to have side effects you couldn't tolerate.
  • Your recent blood or laboratory test results fall within the ranges required by the study.

Who may not be able to join:

  • You have a diagnosis of a type of bowel disease that cannot be clearly classified as UC or CD, or you have a liver condition called primary sclerosing cholangitis.
  • If you have UC, you also have a diagnosis of CD, or vice versa.
  • You have had surgery to remove part of your bowel, or you are likely to need such surgery.
  • You have serious complications from your UC or CD, such as a narrowing of the bowel or short bowel syndrome (some exceptions may apply for CD — confirm with trial site).
  • You have another significant health condition that is not well controlled and could affect your safety or the study results, in the opinion of the study doctor.
  • You have already tried and not responded to more than 5 different approved advanced treatments for UC or CD.
  • You have previously tried a specific type of treatment known as an anti-IL-23p19 antibody and it did not work for you (confirm with trial site if unsure whether your past treatment falls into this category).
  • You are currently taking, or would need to take, certain medications that are not allowed in this study (confirm with trial site for the full list of prohibited medicines).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Contact Lilly at 1-877-CTLILLY (1-877-285-4559) or, Eli Lilly and Company

Phone: 1-317-615-4559

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
4 May 2026
Est. completion
1 June 2027

Where this trial is recruiting

🇧🇪 Belgium 🇧🇷 Brazil 🇨🇦 Canada 🇨🇳 China 🇩🇪 Germany 🇭🇺 Hungary 🇮🇱 Israel 🇮🇹 Italy 🇵🇱 Poland 🇺🇸 United States

Primary endpoints

Number of Participants Allocated to Each of the Intervention-Specific Appendices (ISA)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov